Publication of MGC Pharma Glioblastoma research
MGC Pharmaceuticals Ltd.
MDPI publish peer reviewed academic paper on MGC Pharma research collaboration on the cytotoxic effects of Cannabidiol and Cannabigerol on Glioblastoma stem cells
2 December 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has had a peer reviewed academic paper entitled 'The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling' published by MDPI.
MDPI is the largest open access publisher of peer reviewed academic journals, publishing nearly 400 open access journals and the fifth largest publisher overall in terms of journal paper output. The article has been published as a Molecular Cancer Biology research paper.
The glioblastoma research in the publication is a collaboration between MGC Pharma and the National Institute of Biology, a leading research university in Slovenia[1].
The research paper tests Cannabidiol (CBD) and Cannabigerol (CBG) extracts provided by MGC Pharmaceuticals, and their impact on Glioblastoma cells. The study finds that GPR55 and TRPV1 receptors are the best targets for the antagonistic cannabinoids CBD and CBG (in an optimised mixture) to eliminate Glioblastoma (GBM) stem cells.
This approach avoids using psychoactive tetrahydrocannabinol (THC), which is potentially harmful, particularly in older GBM patients, and should be further tested in animal experiments and clinical trials.
Glioblastoma is a fast growing and aggressive form of cancer, usually starting in the brain. Currently only 5-10% of glioblastoma patients live beyond five years following diagnosis[2].
The article is open access and can be accessed at the following URL:
https://www.mdpi.com/2072-6694/14/23/5918/pdf
--Ends--
Authorised for release by the Managing Director, for further information please contact:
|
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 |
MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
|
UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 |
UK Broker Turner Pope Andy Thacker +44 203 657 0050 |
|
UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 56 minutes ago Judges Scientific
- 1 hour ago AB Dynamics
- 1 hour ago Henry Boot
- 1 hour ago TPXimpact Holdings
- 1 hour ago Ithaca Energy